Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I randomized double-blind placebo-controlled study of FPP003 in healthy adults
jRCT2051220007Phase 1Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2022
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FPP003 in axial spondyloarthritis (axSpA) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Safety endpoints and Immunogenicity endpoints. Started Apr 2022; status: completed.
02
Drugs
FPP003
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on jRCT2051220007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220007.